Overexpression of PIMREG promotes breast cancer aggressiveness via constitutive activation of NF-κB signaling

Abstract

Background It is well-established that activation of nuclear factor-kappa B (NF-κB) signaling plays important roles in cancer development and progression. However, the underlying mechanism by which the NF-κB pathway is constitutively activated in cancer remains largely unclear. The present study aimed to investigate the effect of PICALM interacting mitotic regulator (PIMREG) on sustaining NF-κB activation in breast cancer. Methods The underlying mechanisms in which PIMREG-mediated NF-κB constitutive activation were determined via immunoprecipitation, EMSA and luciferase reporter assays. The expression of PIMREG was examined by quantitative PCR and western blotting analyses and immunohistochemical assay. The effect of PIMREG on aggressiveness of breast cancer cell was measured using MTT, soft agar clonogenic assay, wound healing and transwell matrix penetration assays in vitro and a Xenografted tumor model in vivo . Findings PIMREG competitively interacted with the REL homology domain (RHD) of NF-κB with IκBα, and sustained NF-κB activation by promotion of nuclear accumulation and transcriptional activity of NF-κB via disrupting the NF-κB/IκBα negative feedback loop. PIMREG overexpression significantly enhanced NF-κB transactivity and promoted the breast cancer aggressiveness. The expression of PIMREG was markedly upregulated in breast cancer and positively correlated with clinical characteristics of patients with breast cancer, including the clinical stage, tumor-node-metastasis classification and poorer survival. Interpretation PIMREG promotes breast cancer aggressiveness via disrupting the NF-κB/IκBα negative feedback loop, which suggests that PIMREG might be a valuable prognostic factor and potential target for diagnosis and therapy of metastatic breast cancer. Fund The science foundation of China, Guangdong Province, Guangzhou Education System, and the Science and Technology Program of Guangzhou.

FAM64A: A Novel Oncogenic Target of Lung Adenocarcinoma Regulated by Both Strands of miR-99a (miR-99a-5p and miR-99a-3p)

“…Overexpression of FAM64A was reported in leukemia, lymphoma and several types of solid cancer [ 46 ]. In breast cancer, overexpression of FAM64A enhanced the transactivation of NF-κB by disrupting the NF-κB/IκBα negative feedback loop [ 47 ]. Another study demonstrated that FAM64A regulates STAT3 activation and is involved in Th17 differentiation, colitis and colorectal cancer development [ 48 ].…”

RASSF1A inhibits PDGFB-driven malignant phenotypes of nasopharyngeal carcinoma cells in a YAP1-dependent manner

“…The release of pro-and anti-inflammatory cytokines has a significant role in the triggering of malignant transformation and display of stem cell properties [32][33][34] Gene profiling has yielded important mechanistic insights into the role of PDGFB signaling in RASSF1A-mediated stem cell plasticity. The PDGFB protein encoded by the PDGFB gene in humans is a member of the platelet-derived growth factor family that can be released into the microenvironment as a homodimer (PDGF-BB) or as a heterodimer with the platelet-derived growth factor alpha (PDGFA) polypeptide (PDGF-AB).…”

Prognostic lncRNA, miRNA, and mRNA Signatures in Papillary Thyroid Carcinoma

“…Some of the RNAs have been reported in the previous study. PICALM interacting mitotic regulator (PIMREG) could promote breast cancer aggressiveness via sustaining nuclear factor (NF)-κB activation ( Jiang et al, 2019 ). Progestin and adipoQ receptor family member (PAQR) 4 has been found to compete with S-phase kinase-associated protein (SKP) 2 for binding to the same region in cyclin-dependent kinase (CDK) 4, thereby abrogating SKP2-mediated ubiquitination of CDK4 and contributing to tumorigenesis ( Wang et al, 2017 ).…”